comparemela.com
Home
Live Updates
Finerenone + SGLT2 Inhibitor of Benefit in Diabetes With CKD? : comparemela.com
Finerenone + SGLT2 Inhibitor of Benefit in Diabetes With CKD?
Results from FIDELITY, a prespecified analysis of data from two pivotal trials of finerenone, hints of an additive benefit with SGLT2 inhibitors in patients with type 2 diabetes.
Related Keywords
Asteno
,
Hovedstaden
,
Denmark
,
Charlotte
,
North Carolina
,
United States
,
Kuala Lumpur
,
Malaysia
,
Copenhagen
,
Køavn
,
American
,
Tejas Desai
,
Peter Rossing
,
European Society Of Cardiology Annual Congress
,
Drug Administration
,
American Diabetes Association
,
Us Department Of Veterans Affairs
,
Astrazeneca
,
European Union
,
Steno Diabetes Center
,
World Congress
,
Novo Nordisk
,
Medical Care
,
Medscape Medical
,
New England Journal
,
Veterans Affairs
,
European Society
,
Cardiology Annual Congress
,
European Heart
,
Diabetes Mellitus Type 2
,
Iabetes Mellitus Type Ii
,
Type 2 Diabetes
,
Chronic Renal Failure
,
Hronic Kidney Failure
,
Hronic Kidney Disease Ckd
,
Chronic Kidney Disease
,
Kd
,
Renal Failure
,
Enal Insufficiency
,
Idney Insufficiency
,
Kidney Failure
,
Sglt2 Inhibitors
,
Odium Glucose Transporter 2 Inhibitors
,
Odium Glucose Co Transporter 2 Inhibitors
,
Sodium Glucose Cotransporter 2 Inhibitors
,
Diabetes
,
comparemela.com © 2020. All Rights Reserved.